WHO ICTRP trial
A study of the efficacy and safety to rituximab in treating adult onset…
JPRN-UMIN000021143 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000021143 |
|---|---|
| Public title | A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome |
| Scientific title | A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome - Rituximab to refractory nephrotic syndrome |
| Primary sponsor | Fujita Health University School of Medicine, Department of Nephrology |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Refractory nephrotic syndrome |
| Interventions | an intravenous dose of 375 mg per 1 square meter (maximum 500 mg) once weekly for 4 weeks. |
| Registration date | Feb 23, 2016 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: